Amblyopia is a developmental visual disorder resulting from atypical binocular experience in early childhood that leads to abnormal visual cortex development and vision impairment. Recovery from amblyopia requires significant visual cortex neuroplasticity, i.e. the ability of the central nervous system and its synaptic connections to adapt their structure and function. There is a high level of neuroplasticity in early development and, historically, neuroplastic responses to changes in visual experience were thought to be restricted to a "critical period" in early life. However, as our review now shows, the evidence is growing that plasticity of the adult visual system can also be harnessed to improve vision in amblyopia. Amblyopia treatment involves correcting refractive error to ensure clear and equal retinal image formation in both eyes, then, if necessary, promoting the use of the amblyopic eye by hindering or reducing visual input from the better eye through patching or pharmacologic therapy. Early treatment in children can lead to visual acuity gains and the development of binocular vision in some cases; however, many children do not respond to treatment, and many adults with amblyopia have historically been untreated or undertreated. Here we review the current evidence on how dichoptic training can be used as a novel binocular therapeutic approach to facilitate visual processing of input from the amblyopic eye and can simultaneously engage both eyes in a training task that requires binocular integration. It is a novel and promising treatment for amblyopia in both children and adults., Competing Interests: Declaration of conflicting interestsBT declares royalties/licenses, consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis Pharma AG, Patents planned, issued or pending for binocular treatment of amblyopia (two patents), and Measuring vision in young children (two patents), and is a board member of the International Society for Low Vision Research and Rehabilitation (ISLRR). BT is supported by InnoHK and the Hong Kong SAR Government, NSERC Discovery and CIHR. MCM declares grants or contracts from Television (CNR, Italy), Ecsplain (ERC adv PF7 N 338866), and GenPercpt (ERC Adv N 832813). PB declares support for the present manuscript from NIH (R01EY032162), consulting fees from Novartis Pharma AG, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Department of Optometry, UC Berkeley, San Francisco, CA, USA and Department of Optometry, SUNY, New York, USA, support for attending meetings and/or travel from OptiVis 2022 Symposium, Genoa, Italy, patents planned, issued or pending (Method for Visual Function Assessment Using Binocular Rivalry Bex and Skerswetat Application No: 63/152,331; Self-Administered Adaptive Vision Screening Test Using Angular Indication Bex and Skerswetat U.S. Patent Application No.: 63/309,504; FInD (Foraging Interactive D-prime) - A rapid and general method for efficient and sensitive visual function assessment Bex and Skerswetat U.S. Provisional Patent Application No.: 63/309,504; Portable Brain and Vision Diagnostic and Therapeutic System.Sridhar, Versek, Bex WO2018085598A1; Adaptive Scheduling of Clinical Assessments – Bex, Elze and Ackermann WO2016205521 A1, PCT/US2016/037880; Quantification of inter-ocular suppression in binocular vision impairment - Kwon, Dakin, Wiecek, Bex WO2015179539 A1, PCT/US2015/031806; Prevention and treatment of myopia- Maiello, Vera-Diaz, Bex WO2015027218 A1, PCT/US2014/052398; Spatial Modeling of Visual Fields - Elze, Benner, Bex WO2015027225 A1, PCT/US2014/052414; Measuring Information Acquisition Using Free Recall - Woods, Saunders and Bex WO2014043149 A1, PCT/US2013/059109; Rapid Measurement of Visual Sensitivity - Lesmes, Lu, Dorr and Bex WO2013170091 A1, PCT/US2013/040434), and stock or stock options from Adaptive Sensory Technology (Founder, equity) and PerZeption (Founder, equity). AL is a full-time employee of Novartis Pharmaceuticals and has stock or stock options in Novartis Pharmaceutics. BS is Vice President of the International Society for Low Vision Research and Rehabilitation (ISLRR), shareholder and consultant of SAVIR GmbH Germany, past consultant to Novartis Pharma AG; Various patents issued or pending in the field of vision restoration.